Pharmacokinetics of rifampin and isoniazid in tuberculosis-hivcoinfected patients receiving nevirapine-or efavirenz-based antiretroviral treatment
| Autor(a) principal: | |
|---|---|
| Data de Publicação: | 2014 |
| Outros Autores: | , , , , , , , , , , |
| Tipo de documento: | Artigo |
| Idioma: | eng |
| Título da fonte: | Repositório Institucional da FIOCRUZ (ARCA) |
| Texto Completo: | https://www.arca.fiocruz.br/handle/icict/35177 |
Resumo: | 2020-08-29 |
| id |
CRUZ_60ee82c6110bd70160940efa9d77faff |
|---|---|
| oai_identifier_str |
oai:www.arca.fiocruz.br:icict/35177 |
| network_acronym_str |
CRUZ |
| network_name_str |
Repositório Institucional da FIOCRUZ (ARCA) |
| repository_id_str |
2135 |
| spelling |
Bhatt, N. B.Barau, C.Amin, A.Baudin, E.Meggi, B.,Silva, CFurlan, V.Grinsztejn, BeatrizBarrail-Tran, A.Bonnet, M.Taburet, A. M.ANRS 12146-CARINEMO Study Group2019-08-29T12:05:53Z2019-08-29T12:05:53Z2014BHATT, N. B. et al. Pharmacokinetics of rifampin and isoniazid in tuberculosis-hivcoinfected patients receiving nevirapine-or efavirenz-based antiretroviral treatment. Antimicrobial Agents and Chemotherapy, v. 58, n. 6, p. 3182-3190, 2014.0066-4804https://www.arca.fiocruz.br/handle/icict/3517710.1128/AAC.02379-131098-6596engAmerican Society for MicrobiologyPharmacokinetics of rifampin and isoniazid in tuberculosis-hivcoinfected patients receiving nevirapine-or efavirenz-based antiretroviral treatmentinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/article2020-08-29Ministério da Saúde. Instituto Nacional de Saúde. Maputo, Mozambique / Fundação Oswaldo Cruz. Instituto de Pesquisa Clínica Evandro Chagas. Rio de Janeiro, RJ, Brasil.Assistance Publique Hôpitaux de Paris. Assistance Publique Hôpitaux de Paris. Bicêtre Hospital. Clinical Pharmacy, Paris, France.Assistance Publique Hôpitaux de Paris. Assistance Publique Hôpitaux de Paris. Bicêtre Hospital. Clinical Pharmacy, Paris, France.Epicentre. Paris, France.Ministério da Saúde. Instituto Nacional de Saúde. Maputo, Mozambique.Epicentre. Paris, France.Assistance Publique Hôpitaux de Paris. Assistance Publique Hôpitaux de Paris. Bicêtre Hospital. Clinical Pharmacy, Paris, France.Fundação Oswaldo Cruz. Instituto de Pesquisa Clínica Evandro Chagas. Rio de Janeiro, RJ, Brasil.Assistance Publique Hôpitaux de Paris. Assistance Publique Hôpitaux de Paris. Bicêtre Hospital. Clinical Pharmacy, Paris, France / University Paris Sud. Faculty of Pharmacy. Paris, France.Epicentre. Paris, France.Assistance Publique Hôpitaux de Paris. Assistance Publique Hôpitaux de Paris. Bicêtre Hospital. Clinical Pharmacy, Paris, France.This is a substudy of the Agence Nationale de Recherches sur le Sida et les Hépatites Virales (ANRS) Comparison of Nevirapine and Efavirenz for the Treatment of HIV-TB Co-infected Patients (ANRS 12146-CARINEMO) trial, which assessed the pharmacokinetics of rifampin or isoniazid with or without the coadministration of nonnucleoside reverse transcriptase inhibitor-based HIV antiretroviral therapy in HIV-tuberculosis-coinfected patients in Mozambique. Thirty-eight patients on antituberculosis therapy based on rifampin and isoniazid participated in the substudy (57.9% males; median age, 33 years; median weight, 51.9 kg; median CD4 T cell count, 104 cells/l; median HIV-1 RNA load, 5.5 log copies/ml). The daily doses of rifampin and isoniazid were 10 and 5 mg/kg of body weight, respectively. Twenty-one patients received 200 mg of nevirapine twice a day (b.i.d.), and 17 patients received 600 mg of efavirenz once a day (q.d.) in combination with lamivudine and stavudine from day 1 until the end of the study. Blood samples were collected at regular time-dosing intervals after morning administration of a fixed-dose combination of rifampin and isoniazid. When rifampin was administered alone, the median maximum concentration of drug in serum (Cmax) and the area under the concentration-time curve (AUC) at steady state were 6.59 mg/liter (range, 2.70 to 14.07 mg/ liter) and 27.69 mg · h/liter (range, 11.41 to 109.75 mg · h/liter), respectively. Concentrations remained unchanged when rifampin was coadministered with nevirapine or efavirenz. When isoniazid was administered alone, the median isoniazid Cmax and AUC at steady state were 5.08 mg/liter (range, 1.26 to 11.51 mg/liter) and 20.92 mg · h/liter (range, 7.73 to 56.95 mg · h/liter), respectively. Concentrations remained unchanged when isoniazid was coadministered with nevirapine; however, a 29% decrease in the isoniazid AUC was observed when isoniazid was combined with efavirenz. The pharmacokinetic parameters of rifampin and isoniazid when coadministered with nevirapine or efavirenz were not altered to a clinically significant extent in these severely immunosuppressed HIV-infected patients. Patients experienced favorable clinical outcomes.HIV-tuberculosis coinfectionAntiretroviral treatmentRifampinIsoniazidNevirapineEfavirenzinfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da FIOCRUZ (ARCA)instname:Fundação Oswaldo Cruz (FIOCRUZ)instacron:FIOCRUZLICENSElicense.txttext/plain1748https://www.arca.fiocruz.br/bitstream/icict/35177/1/license.txt8a4605be74aa9ea9d79846c1fba20a33MD51ORIGINALve_Bhatt_N_etal_INI_2014.pdfve_Bhatt_N_etal_INI_2014.pdfapplication/pdf621835https://www.arca.fiocruz.br/bitstream/icict/35177/2/ve_Bhatt_N_etal_INI_2014.pdfcadfb184f2cb879bef44dd91bc027a8fMD52TEXTve_Bhatt_N_etal_INI_2014.pdf.txtve_Bhatt_N_etal_INI_2014.pdf.txtExtracted texttext/plain53596https://www.arca.fiocruz.br/bitstream/icict/35177/3/ve_Bhatt_N_etal_INI_2014.pdf.txt55d0a87f18224f83ae8540270917a176MD53icict/351772023-06-15 16:17:44.488oai:www.arca.fiocruz.br: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Repositório InstitucionalPUBhttps://www.arca.fiocruz.br/oai/requestrepositorio.arca@fiocruz.bropendoar:21352023-06-15T19:17:44Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ)false |
| dc.title.pt_BR.fl_str_mv |
Pharmacokinetics of rifampin and isoniazid in tuberculosis-hivcoinfected patients receiving nevirapine-or efavirenz-based antiretroviral treatment |
| title |
Pharmacokinetics of rifampin and isoniazid in tuberculosis-hivcoinfected patients receiving nevirapine-or efavirenz-based antiretroviral treatment |
| spellingShingle |
Pharmacokinetics of rifampin and isoniazid in tuberculosis-hivcoinfected patients receiving nevirapine-or efavirenz-based antiretroviral treatment Bhatt, N. B. HIV-tuberculosis coinfection Antiretroviral treatment Rifampin Isoniazid Nevirapine Efavirenz |
| title_short |
Pharmacokinetics of rifampin and isoniazid in tuberculosis-hivcoinfected patients receiving nevirapine-or efavirenz-based antiretroviral treatment |
| title_full |
Pharmacokinetics of rifampin and isoniazid in tuberculosis-hivcoinfected patients receiving nevirapine-or efavirenz-based antiretroviral treatment |
| title_fullStr |
Pharmacokinetics of rifampin and isoniazid in tuberculosis-hivcoinfected patients receiving nevirapine-or efavirenz-based antiretroviral treatment |
| title_full_unstemmed |
Pharmacokinetics of rifampin and isoniazid in tuberculosis-hivcoinfected patients receiving nevirapine-or efavirenz-based antiretroviral treatment |
| title_sort |
Pharmacokinetics of rifampin and isoniazid in tuberculosis-hivcoinfected patients receiving nevirapine-or efavirenz-based antiretroviral treatment |
| author |
Bhatt, N. B. |
| author_facet |
Bhatt, N. B. Barau, C. Amin, A. Baudin, E. Meggi, B., Silva, C Furlan, V. Grinsztejn, Beatriz Barrail-Tran, A. Bonnet, M. Taburet, A. M. ANRS 12146-CARINEMO Study Group |
| author_role |
author |
| author2 |
Barau, C. Amin, A. Baudin, E. Meggi, B., Silva, C Furlan, V. Grinsztejn, Beatriz Barrail-Tran, A. Bonnet, M. Taburet, A. M. ANRS 12146-CARINEMO Study Group |
| author2_role |
author author author author author author author author author author author |
| dc.contributor.author.fl_str_mv |
Bhatt, N. B. Barau, C. Amin, A. Baudin, E. Meggi, B., Silva, C Furlan, V. Grinsztejn, Beatriz Barrail-Tran, A. Bonnet, M. Taburet, A. M. ANRS 12146-CARINEMO Study Group |
| dc.subject.en.pt_BR.fl_str_mv |
HIV-tuberculosis coinfection Antiretroviral treatment Rifampin Isoniazid Nevirapine Efavirenz |
| topic |
HIV-tuberculosis coinfection Antiretroviral treatment Rifampin Isoniazid Nevirapine Efavirenz |
| description |
2020-08-29 |
| publishDate |
2014 |
| dc.date.issued.fl_str_mv |
2014 |
| dc.date.accessioned.fl_str_mv |
2019-08-29T12:05:53Z |
| dc.date.available.fl_str_mv |
2019-08-29T12:05:53Z |
| dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
| dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
| format |
article |
| status_str |
publishedVersion |
| dc.identifier.citation.fl_str_mv |
BHATT, N. B. et al. Pharmacokinetics of rifampin and isoniazid in tuberculosis-hivcoinfected patients receiving nevirapine-or efavirenz-based antiretroviral treatment. Antimicrobial Agents and Chemotherapy, v. 58, n. 6, p. 3182-3190, 2014. |
| dc.identifier.uri.fl_str_mv |
https://www.arca.fiocruz.br/handle/icict/35177 |
| dc.identifier.issn.pt_BR.fl_str_mv |
0066-4804 |
| dc.identifier.doi.none.fl_str_mv |
10.1128/AAC.02379-13 |
| dc.identifier.eissn.none.fl_str_mv |
1098-6596 |
| identifier_str_mv |
BHATT, N. B. et al. Pharmacokinetics of rifampin and isoniazid in tuberculosis-hivcoinfected patients receiving nevirapine-or efavirenz-based antiretroviral treatment. Antimicrobial Agents and Chemotherapy, v. 58, n. 6, p. 3182-3190, 2014. 0066-4804 10.1128/AAC.02379-13 1098-6596 |
| url |
https://www.arca.fiocruz.br/handle/icict/35177 |
| dc.language.iso.fl_str_mv |
eng |
| language |
eng |
| dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
| eu_rights_str_mv |
openAccess |
| dc.publisher.none.fl_str_mv |
American Society for Microbiology |
| publisher.none.fl_str_mv |
American Society for Microbiology |
| dc.source.none.fl_str_mv |
reponame:Repositório Institucional da FIOCRUZ (ARCA) instname:Fundação Oswaldo Cruz (FIOCRUZ) instacron:FIOCRUZ |
| instname_str |
Fundação Oswaldo Cruz (FIOCRUZ) |
| instacron_str |
FIOCRUZ |
| institution |
FIOCRUZ |
| reponame_str |
Repositório Institucional da FIOCRUZ (ARCA) |
| collection |
Repositório Institucional da FIOCRUZ (ARCA) |
| bitstream.url.fl_str_mv |
https://www.arca.fiocruz.br/bitstream/icict/35177/1/license.txt https://www.arca.fiocruz.br/bitstream/icict/35177/2/ve_Bhatt_N_etal_INI_2014.pdf https://www.arca.fiocruz.br/bitstream/icict/35177/3/ve_Bhatt_N_etal_INI_2014.pdf.txt |
| bitstream.checksum.fl_str_mv |
8a4605be74aa9ea9d79846c1fba20a33 cadfb184f2cb879bef44dd91bc027a8f 55d0a87f18224f83ae8540270917a176 |
| bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 MD5 |
| repository.name.fl_str_mv |
Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ) |
| repository.mail.fl_str_mv |
repositorio.arca@fiocruz.br |
| _version_ |
1798324832879771648 |